BACKGROUND: Alcohol use disorders (AUDs) are a frequent comorbidity in a large percentage of people living with HIV/AIDS (PLWHA). PLWHA with comorbid AUDs are consistently found to perform poorly at most levels of the HIV treatment cascade, resulting in a higher likelihood of virologic nonsuppression. This has been partly attributed to lower rates of persistence with and adherence to antiretroviral therapies (ART). Focus groups of in-care PLWHA identify the need to suspend ART on drinking days because of the potential for toxicity and/or lack of therapeutic effectiveness. The aim of this study was to examine whether chronic binge alcohol (CBA) consumption decreases the effectiveness of uninterrupted ART, specifically that of nucleoside reverse-transcriptase inhibitors (NRTI) tenofovir and emtricitabine in suppressing viral replication, or results in drug toxicity in simian immunodeficiency virus (SIV)-infected rhesus macaques. METHODS: Daily CBA or isocaloric sucrose (SUC) administration was initiated 3 months prior to intrarectal SIVmac251 inoculation and continued throughout the study period. ART was initiated 2.5 months after SIV infection and continued through the study period. RESULTS: CBA administration did not prevent or delay the ART-mediated reduction in viral load. Following ART, circulating levels of total protein and creatinine were significantly higher than baseline values in both SUC- and CBA-treated animals, but still within a normal range. No evidence of ART toxicity was observed in either CBA- or SUC-administered macaques. CONCLUSIONS: These findings indicate that CBA does not attenuate effectiveness of NRTI suppression of viral load, nor does it appear to interact with NRTI to produce toxicity during the initial 2 months of treatment. We conclude that while efforts to reduce AUD in PLWHA should be a priority, counseling on the importance of adherence to ART even on drinking days should also be promoted.
BACKGROUND:Alcohol use disorders (AUDs) are a frequent comorbidity in a large percentage of people living with HIV/AIDS (PLWHA). PLWHA with comorbid AUDs are consistently found to perform poorly at most levels of the HIV treatment cascade, resulting in a higher likelihood of virologic nonsuppression. This has been partly attributed to lower rates of persistence with and adherence to antiretroviral therapies (ART). Focus groups of in-care PLWHA identify the need to suspend ART on drinking days because of the potential for toxicity and/or lack of therapeutic effectiveness. The aim of this study was to examine whether chronic binge alcohol (CBA) consumption decreases the effectiveness of uninterrupted ART, specifically that of nucleoside reverse-transcriptase inhibitors (NRTI) tenofovir and emtricitabine in suppressing viral replication, or results in drug toxicity in simian immunodeficiency virus (SIV)-infected rhesus macaques. METHODS: Daily CBA or isocaloric sucrose (SUC) administration was initiated 3 months prior to intrarectal SIVmac251 inoculation and continued throughout the study period. ART was initiated 2.5 months after SIV infection and continued through the study period. RESULTS:CBA administration did not prevent or delay the ART-mediated reduction in viral load. Following ART, circulating levels of total protein and creatinine were significantly higher than baseline values in both SUC- and CBA-treated animals, but still within a normal range. No evidence of ARTtoxicity was observed in either CBA- or SUC-administered macaques. CONCLUSIONS: These findings indicate that CBA does not attenuate effectiveness of NRTI suppression of viral load, nor does it appear to interact with NRTI to produce toxicity during the initial 2 months of treatment. We conclude that while efforts to reduce AUD in PLWHA should be a priority, counseling on the importance of adherence to ART even on drinking days should also be promoted.
Authors: J D Lifson; M Piatak; A N Cline; J L Rossio; J Purcell; I Pandrea; N Bischofberger; J Blanchard; R S Veazey Journal: J Med Primatol Date: 2003-08 Impact factor: 0.667
Authors: Carolyn M Jarvis; Laura L Hayman; Lynne T Braun; Dorie W Schwertz; Carol Estwing Ferrans; Mariann R Piano Journal: J Cardiovasc Nurs Date: 2007 Nov-Dec Impact factor: 2.083
Authors: Gregory J Bagby; David A Stoltz; Ping Zhang; Jay K Kolls; Julie Brown; Rudolf P Bohm; Richard Rockar; Jeanette Purcell; Michael Murphey-Corb; Steve Nelson Journal: Alcohol Clin Exp Res Date: 2003-03 Impact factor: 3.455
Authors: L Simon; S M Ford; K Song; P Berner; C Vande Stouwe; S Nelson; G J Bagby; P E Molina Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-06-21 Impact factor: 3.619
Authors: Giraldina Trevejo-Nunez; Kong Chen; Jason P Dufour; Gregory J Bagby; William T Horne; Steve Nelson; Jay K Kolls Journal: Infect Immun Date: 2015-03-09 Impact factor: 3.441
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455
Authors: Stephen M Ford; Liz Simon; Curtis Vande Stouwe; Tim Allerton; Donald E Mercante; Lauri O Byerley; Jason P Dufour; Gregory J Bagby; Steve Nelson; Patricia E Molina Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-09-07 Impact factor: 3.619
Authors: Paige S Katz; Robert W Siggins; Connie Porretta; Megan L Armstrong; Arnold H Zea; Donald E Mercante; Christopher Parsons; Ronald S Veazey; Gregory J Bagby; Steve Nelson; Patricia E Molina; David A Welsh Journal: Alcohol Date: 2015-10-27 Impact factor: 2.405
Authors: Stephen M Ford; Liz Simon Peter; Paul Berner; Garth Cook; Curtis Vande Stouwe; Jason Dufour; Gregory Bagby; Steve Nelson; Patricia E Molina Journal: Am J Physiol Endocrinol Metab Date: 2018-07-24 Impact factor: 4.310
Authors: Patricia E Molina; Liz Simon; Angela M Amedee; David A Welsh; Tekeda F Ferguson Journal: Alcohol Alcohol Date: 2018-07-01 Impact factor: 2.826